{
    "id": 518,
    "fullName": "IDH1 wild-type",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "Wild-type IDH1 indicates that no mutation has been detected within the IDH1 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 3417,
        "geneSymbol": "IDH1",
        "terms": [
            "IDH1",
            "HEL-216",
            "HEL-S-26",
            "IDCD",
            "IDH",
            "IDP",
            "IDPC",
            "PICD"
        ]
    },
    "variant": "wild-type",
    "createDate": "05/13/2014",
    "updateDate": "04/25/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 13759,
            "approvalStatus": "Guideline",
            "evidenceType": "Risk Factor",
            "efficacyEvidence": "IDH1 wild-type is associated with increased risk of aggressive disease in patients with grade II or III infiltrative gliomas (NCCN.org).",
            "molecularProfile": {
                "id": 576,
                "profileName": "IDH1 wild-type"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 3070,
                "name": "malignant glioma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13407,
            "approvalStatus": "Guideline",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "The presence of a TERT mutation, in the absence of an IDH mutation, is associated with reduced overall survival in patients with diffusely infiltrative gliomas (NCCN.org).",
            "molecularProfile": {
                "id": 29114,
                "profileName": "IDH1 wild-type IDH2 wild-type TERT mut"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 3070,
                "name": "malignant glioma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16067,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, PTEN mutations were significantly enriched in patients with IDH1 wild-type glioblastoma who did not respond to anti-PD-1 therapy with either Keytruda (pembrolizumab) or Opdivo (nivolumab), compared to those who responded (odds ratio=0.85, p=0.0063), with 23 PTEN mutations identified in 32 non-responders and 3 in 13 responders (PMID: 30742119).",
            "molecularProfile": {
                "id": 31465,
                "profileName": "IDH1 wild-type PTEN mut"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14204,
                    "pubMedId": 30742119,
                    "title": "Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30742119"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16066,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, PTEN mutations were significantly enriched in patients with IDH1 wild-type glioblastoma who did not respond to anti-PD-1 therapy, with either Keytruda (pembrolizumab) or Opdivo (nivolumab), compared to those who responded (odds ratio=0.85, p=0.0063), with 23 PTEN mutations identified in 32 non-responders and 3 in 13 responders (PMID: 30742119).",
            "molecularProfile": {
                "id": 31465,
                "profileName": "IDH1 wild-type PTEN mut"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14204,
                    "pubMedId": 30742119,
                    "title": "Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30742119"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16068,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, MAPK pathway mutations were significantly enriched in patients with IDH1 wild-type glioblastoma who responded to anti-PD-1 therapy with either Keytruda (pembrolizumab) or Opdivo (nivolumab), compared to those who did not respond (odds ratio=12.8, p=0.019), with 4 MAPK pathway mutations (2 in BRAF, 2 in PTPN11) identified in 13 responders and 1 (BRAF) in 32 non-responders (PMID: 30742119).",
            "molecularProfile": {
                "id": 31466,
                "profileName": "BRAF mut IDH1 wild-type"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14204,
                    "pubMedId": 30742119,
                    "title": "Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30742119"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16069,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, MAPK pathway mutations were significantly enriched in patients with IDH1 wild-type glioblastoma who responded to anti-PD-1 therapy with either Keytruda (pembrolizumab) or Opdivo (nivolumab), compared to those who did not respond (odds ratio=12.8, p=0.019), with 4 MAPK pathway mutations (2 in BRAF, 2 in PTPN11) identified in 13 responders and 1 (BRAF) in 32 non-responders (PMID: 30742119).",
            "molecularProfile": {
                "id": 31466,
                "profileName": "BRAF mut IDH1 wild-type"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14204,
                    "pubMedId": 30742119,
                    "title": "Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30742119"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16071,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, MAPK pathway mutations were significantly enriched in patients with IDH1 wild-type glioblastoma who responded to anti-PD-1 therapy with either Keytruda (pembrolizumab) or Opdivo (nivolumab), compared to those who did not respond (odds ratio=12.8, p=0.019), with 4 MAPK pathway mutations (2 in BRAF, 2 in PTPN11) identified in 13 responders and 1 (BRAF) in 32 non-responders (PMID: 30742119).",
            "molecularProfile": {
                "id": 31467,
                "profileName": "IDH1 wild-type PTPN11 mut"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14204,
                    "pubMedId": 30742119,
                    "title": "Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30742119"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16070,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, MAPK pathway mutations were significantly enriched in patients with IDH1 wild-type glioblastoma who responded to anti-PD-1 therapy with either Keytruda (pembrolizumab) or Opdivo (nivolumab), compared to those who did not respond (odds ratio=12.8, p=0.019), with 4 MAPK pathway mutations (2 in BRAF, 2 in PTPN11) identified in 13 responders and 1 (BRAF) in 32 non-responders (PMID: 30742119).",
            "molecularProfile": {
                "id": 31467,
                "profileName": "IDH1 wild-type PTPN11 mut"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14204,
                    "pubMedId": 30742119,
                    "title": "Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30742119"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17366,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Crenolanib, decreased cell proliferation of transformed mouse cells expressing Flt3 D835Y and Idh1 wild-type (PMID: 30651561).",
            "molecularProfile": {
                "id": 32520,
                "profileName": "FLT3 D835Y IDH1 wild-type"
            },
            "therapy": {
                "id": 705,
                "therapyName": "Crenolanib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15390,
                    "pubMedId": 30651561,
                    "title": "Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30651561"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17368,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Crenolanib, in combination with AGI-5198, synergistically decreased cell proliferation of transformed mouse cells expressing Flt3 D835Y and Idh1 wild-type (PMID: 30651561).",
            "molecularProfile": {
                "id": 32520,
                "profileName": "FLT3 D835Y IDH1 wild-type"
            },
            "therapy": {
                "id": 8466,
                "therapyName": "AGI-5198 + Crenolanib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15390,
                    "pubMedId": 30651561,
                    "title": "Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30651561"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17363,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AGI-5198, did not decrease cell proliferation of transformed mouse cells expressing Flt3 D835Y and Idh1 wild-type (PMID: 30651561).",
            "molecularProfile": {
                "id": 32520,
                "profileName": "FLT3 D835Y IDH1 wild-type"
            },
            "therapy": {
                "id": 2569,
                "therapyName": "AGI-5198",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15390,
                    "pubMedId": 30651561,
                    "title": "Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30651561"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 576,
            "profileName": "IDH1 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29114,
            "profileName": "IDH1 wild-type IDH2 wild-type TERT mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31465,
            "profileName": "IDH1 wild-type PTEN mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31466,
            "profileName": "BRAF mut IDH1 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31467,
            "profileName": "IDH1 wild-type PTPN11 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32520,
            "profileName": "FLT3 D835Y IDH1 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}